Please login to the form below

enadenotucirev

This page shows the latest enadenotucirev news and features for those working in and with pharma, biotech and healthcare.

Bristol-Myers Squibb acquires Cormorant for $520m

That project will look at the safety and efficacy of enadenotucirev - which is made by PsiOxus Therapeutics in Oxford, UK - in combination with Opdivo for the treatment of a range of

Latest news

BMS to explore new options for its immuno-oncology drug Opdivo

Enadenotucirev is designed to have immune stimulating effects and the companies hope that combining it with Opdivo, which alleviates immune suppression, will improve tumour shrinkage and treatment durability. ... BMS has then reserved the rights to first

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Client Services Director- Flexible Working: Negotiable

Senior Medical Writer: Competitive salary plus benefits

Account Manager – Healthcare advertising: Salary TBC

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Account Director – UK Office: Excellent salary and benefits

Events Executive: DOE

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Subscribe to our email news alerts

PMHub

Add my company

infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

Report: Customer experience, shaping digital healthcare: In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Encouraging signs in biomarker R&D: The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it: What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...